BRIEF-Vascular Biogenics - Following Execution Of Term Sheet With Wellbeing Group On June 30, Parties Negotiated A Definitive Asset Purchase Agreement

Reuters2023-10-03

Oct 2 (Reuters) - Vascular Biogenics Ltd :

* VASCULAR BIOGENICS- FOLLOWING EXECUTION OF TERM SHEET WITH WELLBEING GROUP ON JUNE 30, PARTIES NEGOTIATED A DEFINITIVE ASSET PURCHASE AGREEMENT

* VASCULAR BIOGENICS- DEFINITIVE ASSET PURCHASE AGREEMENT FOR SALE OF VB-601 AND MOSPD2 RELATED ASSETS

* VASCULAR BIOGENICS LTD - VBL ENTERED INTO ASSET PURCHASE AGREEMENT ON OCTOBER 1, 2023

Further company coverage:

((Reuters.briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2372853261?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-10-03 05:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2372853261","market":"us","top_or_hot":-1,"title":"BRIEF-Vascular Biogenics - Following Execution Of Term Sheet With Wellbeing Group On June 30, Parties Negotiated A Definitive Asset Purchase Agreement","media":"Reuters","content":"<html><body><p>Oct 2 (Reuters) - <a href=\"https://laohu8.com/S/VBLT\">Vascular Biogenics Ltd</a>   :</p><p>   * VASCULAR BIOGENICS-  FOLLOWING EXECUTION OF TERM SHEET WITH WELLBEING GROUP ON JUNE 30, PARTIES NEGOTIATED A DEFINITIVE ASSET PURCHASE AGREEMENT</p><p>   * VASCULAR BIOGENICS-  DEFINITIVE ASSET PURCHASE AGREEMENT FOR SALE OF VB-601 AND MOSPD2 RELATED ASSETS</p><p>   * VASCULAR BIOGENICS LTD - VBL ENTERED INTO ASSET PURCHASE AGREEMENT ON OCTOBER 1, 2023</p><p>Further company coverage:   </p><p> ((Reuters.briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Vascular Biogenics - Following Execution Of Term Sheet With Wellbeing Group On June 30, Parties Negotiated A Definitive Asset Purchase Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Vascular Biogenics - Following Execution Of Term Sheet With Wellbeing Group On June 30, Parties Negotiated A Definitive Asset Purchase Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-03 05:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 2 (Reuters) - Vascular Biogenics Ltd   :   * VASCULAR BIOGENICS-  FOLLOWING EXECUTION OF TERM SHEET WITH WELLBEING GROUP ON JUNE 30, PARTIES NEGOTIATED A DEFINITIVE ASSET PURCHASE AGREEMENT   * ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861215975.USD","symbol_name":"贝莱德新一代科技基金 A2","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2372853261","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2372853261","pubTimestamp":1696282740,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 2  - Vascular Biogenics Ltd   :   * VASCULAR BIOGENICS-  FOLLOWING EXECUTION OF TERM SHEET WITH WELLBEING GROUP ON JUNE 30, PARTIES NEGOTIATED A DEFINITIVE ASSET PURCHASE AGREEMENT   * VASCULAR BIOGENICS-  DEFINITIVE ASSET PURCHASE AGREEMENT FOR SALE OF VB-601 AND MOSPD2 RELATED ASSETS   * VASCULAR BIOGENICS LTD - VBL ENTERED INTO ASSET PURCHASE AGREEMENT ON OCTOBER 1, 2023Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861215975.USD":"贝莱德新一代科技基金 A2","BK4588":"碎股","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","ON":"安森美半导体","BK4512":"苹果概念","BK4139":"生物科技","BK4141":"半导体产品","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","BK4585":"ETF&股票定投概念","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1548497426.USD":"安联环球人工智能AT Acc","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC"},"translate_title":"简介——血管生物技术——继6月30日与福利集团签署条款清单后，双方就最终资产购买协议进行了谈判","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VBLT":1,"ON":0.62},"content_text":"Oct 2 (Reuters) - Vascular Biogenics Ltd   :   * VASCULAR BIOGENICS-  FOLLOWING EXECUTION OF TERM SHEET WITH WELLBEING GROUP ON JUNE 30, PARTIES NEGOTIATED A DEFINITIVE ASSET PURCHASE AGREEMENT   * VASCULAR BIOGENICS-  DEFINITIVE ASSET PURCHASE AGREEMENT FOR SALE OF VB-601 AND MOSPD2 RELATED ASSETS   * VASCULAR BIOGENICS LTD - VBL ENTERED INTO ASSET PURCHASE AGREEMENT ON OCTOBER 1, 2023Further company coverage:    ((Reuters.briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2372853261"}